Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31168802 | 1.00 | FAAH (0.54) | FAAHMGLLKDM4EALDH1A1KDM4C | |
| SCHEMBL31168848 | 0.93 | FAAH (0.52) | FAAHMGLLKDM4EALDH1A1KDM4C | |
| SCHEMBL21821113 | 0.93 | FAAH (0.52) | FAAHMGLLKDM4EALDH1A1KDM4C | |
| SCHEMBL20503526 | 0.90 | MGLL (0.49) | FAAHMGLLKDM4EALDH1A1KDM4C | |
| SCHEMBL21821066 | 0.88 | FAAH (0.51) | FAAHMGLL | |
| SCHEMBL31168808 | 0.88 | FAAH (0.51) | FAAHMGLL | |
| SCHEMBL31168831 | 0.86 | FAAH (0.72) | FAAHMGLLPHGDH | |
| SCHEMBL21821080 | 0.86 | FAAH (0.72) | FAAHMGLLPHGDH | |
| SCHEMBL21821063 | 0.85 | FAAH (0.54) | FAAHMGLLKDM4EALDH1A1KDM4C | |
| SCHEMBL31168789 | 0.85 | FAAH (0.54) | FAAHMGLLKDM4EALDH1A1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | FAAH 112/4885MGLL 4/4885KDM4E 3708/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | FAAH 112/4885MGLL 4/4885KDM4E 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.